Active Member
|
[China]
Address: No.6, kingdee road, kunshan city, jiangsu province., Suzhou, Jiangsu,china
Contact name:Anna li
KunShan JiAn Biotech Co., Ltd. |
|
|
Antigen Rapid Test Kit Self Test Influenza Antigen Flu A B Rapid Test
Description
Influenza is a highly contagious acute viral infection of the respiratory tract. It is a communicable disease easily transmitted from person to person through aerosol droplets excreted when sneezing and coughing. Common symptoms include high fever, chills, headache, cough, sore throat, and malaise. The type A influenza virus is more prevalent and is the primary pathogen associated with serious epidemics. The type B virus causes a disease that is generally not as severe as that caused by the type A virus.
An accurate diagnosis of influenza based on clinical symptoms is difficult because the initial symptoms of influenza are similar to those of numerous other illnesses. Therefore, it can be confirmed only by laboratory diagnostic testing. Early differential diagnosis of influenza type A or type B can allow for proper treatment with appropriate antiviral therapy while reducing the incidence of inappropriate treatment with antibiotics. Early diagnosis and treatment are of particular value in a clinical setting where an accurate diagnosis can assist the healthcare professional with the management of influenza patients who are at risk for complications. FLU A&B Antigen Test kit(Colloidal Gold Method) is a rapid immunoassay to be used as an aid for the differential diagnosis of influenza type A and type B.
Specification
| suitable for the crowd | Everyone including the elderly and children |
| Test time | 15 mins |
| Features | Portable, easy carry, accuracy, sensitivity, specificity |
| Brands | Test kits and packages both can be customized |
| Usage | FLU A&B Antigen Test kit(Colloidal Gold Method) is an in vitro rapid qualitative test that detects influenza type A and type B nucleoprotein antigens directly from nasal swab and nasopharyngeal swab specimens were obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections |
| Methodology | Colloidal Gold Immune Chromatographic Assay |
Picture details
CE Approved
All our rapid test kits have CE certifications that can be downloaded.
15 types of fast test ce certifications.pdf
Main components
The test kit consists of a test cassette, Extraction Reagent, Sterile Swabs, and Sample Extraction Tubes.
| No. | Components | Main ingredients |
| 1 | FLU A&B test cassette (Colloidal Gold Method) | The test card consists of a desiccant and a test strip. The test strip consists of a sample pad and a gold label pad (fixed with a colloidal gold-marked FLU A antibodyⅠand FLU B antibodyⅠ), a nitrocellulose membrane (coated with FLU A antibodyⅡand FLU B antibodyⅡ, goat anti-mouse IgG polyclonal antibody as the quality control line (C line)), absorbent paper and PVC rubber plate composition. 1 piece for 1 test/kit |
| 2 | Extraction Reagent | 1 tube for 1 test/kit |
| 3 | Sterile Swabs | 1 piece for 1 test/kit |
| 4 | Extraction Tubes | 1 piece for 1 test/kit |
Warning and precautions
1. Do not use the test kit if the pouch is damaged or the seal is broken.
2. Do not use this kit beyond the expiration date printed on the package label.
3. To avoid erroneous results, specimens must be processed as indicated in the assay procedure section.
4. Do not reuse any kit components.
5. Specific training or guidance is recommended if operators are inexperienced in specimen collection and handling. Wear protective clothing such as a lab coat, disposable gloves, and eye protection when specimen collection and analysis. Pathogenic microorganisms, including hepatitis virus and human immunodeficiency virus, may be present in clinical specimens.
6. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. A viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive culture specimens.
